Ultrastructural Studies of Platelet Aggregates from Human Subjects Receiving Clopidogrel and from a Patient with an Inherited Defect of an ADP-Dependent Pathway of Platelet Activation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 12, 1996, Pages 1532-1543

  Humbert, Michel ^a   Nurden, Paquita ^a   Bihour, Claude ^a   Pasquet, Jean Max ^a   Winckler, Joëlle ^a   Heilmann, Eric ^a   Savi, Pierre ^b   Herbert, Jean Marc ^b   Kunicki, Thomas J ^c   Nurden, Alan T ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b SANOFI   (France)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ADP; Clopidogrel; Fibrinogen; GP IIb IIIa complexes; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR;

ARTICLE; BLOOD CLOTTING; CALCIUM TRANSPORT; CASE REPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE SHAPE;

ADENOSINE DIPHOSPHATE; ADULT; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; TICLOPIDINE;

EID: 0030482497     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.12.1532     Document Type: Article

References (52)

1. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-929.
2. Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood. 1978;52:453-466.
3. Packham MA. Role of platelets in thrombosis and haemostasis. Can J Physiol Pharmacol. 1994;72:278-284.
4. Maffrand JP, Bernat A, Delebassée D, Cazenave J-P, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemost. 1988;59:225-230.
5. Herbert JM, Frehel D, Vallée E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993;11:180-198.
6. Flores-Runk P, Raasch RH. Ticlopidine and anti-platelet therapy. Ann Pharmacother. 1993;27:1090-1098.
7. David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res. 1993;14:35-49.
8. Feliste R, Delebassée D, Simon MF, Chap H, Defreyn G, Vallée E, Dousle-Blazy L, Maffrand JP. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987;48:403-415.
9. Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets. Thromb Haemost. 1990;64:150-155.
10. Roald HE, Barstad RM, Kierulf P, Skorten F, Dickinson JP, Kieffer G, Sakariassen KS. Clopidogrel, a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost. 1994;71:655-662.
11. Roald HE, Sakariassen KS. Axial dependence of collagen-induced thrombus formation in flowing non-anticoagulated human blood. Thromb Haemost. 1995;73:126-131.
12. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985;75:328-338.
13. Gachet C, Stierle A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, Maffrand JP. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229-238.
14. 1. Biochem Pharmacol. 1990;40:2683-2687.
15. 1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186-190.
16. 32P)diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry. 1982;21: 544-549.
17. 32P) diphosphate: an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest. 1983;71:420-428.
18. Mills DCB, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of adenylate cyclase. Anerioscler Thromb. 1992;12:430-436.
19. 3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994;269:772-777.
20. Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave J-P. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two receptors. Br J Haematol. 1995;91:434-444.
21. Savi P, Heilmann E, Nurden P, Laplace MCL, Bihour C, Kieffer G, Nurden AT, Herbert JM. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 1996;2:35-42.
22. 3 in resting and activated human platelets determined by expression of a novel class of ligand-binding sites (LIBS) recognized by monoclonal antibody AP6. Blood. 1995;88:887-899.
23. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden AT. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: evidence for more than one pathway of GP IIb-IIIa complex activation. J Clin Invest. 1995;95:1612-1622.
24. Kouns WC, Steiner B, Kunicki TJ, Moog S, Jutzi J, Jennings LK, Cazenave JP, Lanza F. Activation of the fibrinogen binding site on platelets isolated from a patient with the Strasbourg I variant of Glanzmann's thrombasthenia. Blood. 1994;84:1108-1116.
25. Gralnick HR, Williams SB, McKeown L, Shafer B, Connaghan GD, Hansmann K, Vail M, Magruder L. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol. 1992;80:347-357.
26. Xia Z, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophys J. 1994;66:2190-2201.
27. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis. 1995;6:395-410.
28. Heilmann E, Hourdillé P, Pruvost A, Paponneau A, Nurden AT. Thrombin-induced platelet aggregates have a dynamic structure: time-dependent redistribution of glycoprotein IIb/IIIa complexes and secreted adhesive proteins. Arterioscler Thromb. 1991;11:704-718.
29. Hourdillé P, Heilmann E, Winckler J, Clemetson KJ, Nurden AT. Thrombin induces a rapid distribution of GP Ib-IX complexes within the membrane systems of activated human platelets. Blood. 1990; 76:1503-1513.
30. Hourdillé P, Gralnick HR, Heilmann E, Derlon A, Ferrer AM, Vezon G, Nurden AT. von Willebrand factor bound to glycoprotein Ib is cleared from the platelet surface after platelet activation by thrombin. Blood. 1992;79:2011-2021.
31. 2+-ATPase inhibitors. Biochemistry. 1995;34:11625-11634.
32. Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost. 1991; 66:694-699.
33. Cattaneo MB, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80:2787-2796.
34. Savi P, Combalbert J, Gaich C, Roucjon M-C, Maffrand J-P, Berger Y, Herbert J-M. The anti-aggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317.
35. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340-348.
36. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65:467-473.
37. 2 formation on close contact of human platelets in media with low concentration of ionized calcium. Blood. 1987;70:647-651.
38. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost. 1989;62:968-976.
39. Janes SL, Wilson DJ, Cox AD, Chronos NAF, Goodall AH. ADP causes partial degranulation of platelets in the absence of aggregation. Br J Haematol. 1994;86:568-573.
40. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood. 1993;82:505-512.
41. Hattori A, Ito S, Tsukada T, Koike K, Matsuoka M. Ultrastructure of platelet aggregation at an early stage. In: Didisheim P, Shimamoto T, Yamazaki H, eds. Platelets, Thrombosis and Inhibitors. Stuttgart, Germany: FK Schattauer Verlag; 1973:147-158.
42. Suzuki H, Kinlough-Rathbone RL, Packham MA, Tanoue K, Yamazaki H, Mustard JF. Immunocytochemical localization of fibrinogen on washed human platelets: lack of requirement for fibrinogen during adenosine diphosphate-induced responses and enhanced fibrinogen binding in a medium with low calcium levels. Blood. 1988;71:850-860.
43. Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megacaryocyte granules. J Clin Invest. 1989;84:73-82.
44. Wencel Drake JD, Frelinger AL, Dieter MG, Lam CT. Arg-Gly-Asp-dependent occupancy of GP IIb-IIIa by applagin: evidence for internalization and cycling of a platelet integrin. Blood. 1993; 81:62-69.
45. George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med. 1984;311:1084-1098.
46. Harfenist EJ, Packham MA, Mustard JF. Reversibility of the association of fibrinogen with rabbit platelets exposed to ADP. Blood. 1980;56:189-198.
47. Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980;55:841-847.
48. Isenberg WM, McEver RP, Phillips DR, Shuman MA, Bainton DF. The platelet fibrinogen receptor: an immunogold-surface replica study of agonist-induced ligand binding and receptor clustering. J Cell Biol. 1987;104:1655-1663.
49. Feliste R, Simon M-F, Chap H, Douste-Blazy L, Defreyn G, Maffrand J-P. Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets. Biochem Pharmacol. 1988;37:2559-2564.
50. Hourani MO, Hall DA. Receptors for ADP on human blood platelets. Trends Pharmacol Sci. 1994;15:103-108.
51. Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res. 1995;80:209-216.
52. Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Arterioscler Thromb. 1994;14:1466-1474.